1372P Repotrectinib in patients (pts) with NTRK fusion-positive (NTRK+) advanced solid tumors, including NSCLC: Update from the phase I/II TRIDENT-1 trial
| Autor: | Solomon, B.J., Drilon, A., Lin, J.J., Bazhenova, L., Goto, K., De Langen, J., Kim, D-W., Wolf, J., Springfeld, C., Popat, S., Lim, D.W-T., Baik, C.S., Hervieu, A., Moreno Garcia, V., Yang, N., Thamake, S., Ades, F., Trone, D., Besse, B. |
|---|---|
| Zdroj: | In Annals of Oncology October 2023 34 Supplement 2:S787-S788 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|